drugset / Trial / NCT01580969
Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of step 1 is the rate of adverse events of minocycline and bevacizumab during reirradiation and of step 2 is the response rate to bevacizumab, reirradiation, and minocycline. The secondary objectives are the response rate, Progression Free Survival (PFS)-3, PFS-6, and effects on quality of life and cognition from repeat radiation and bevacizumab.
Timeline
- Start
- 2012-07-06
- Primary completion
- 2018-01-12
- Completion
- 2018-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Minocycline | Small molecule | 100 mg | Oral |
| Subject | Minocycline | Small molecule | 200 mg | Oral |
| Subject | Minocycline | Small molecule | 400 mg | Oral |